Q-omics provides the consensus-scored NAV2-AS2 profile across patient tissues and cancer cell-line models. NAV2-AS2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NAV2-AS2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, NAV2-AS2 RNA expression shows 11,771 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where NAV2-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAV2-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAV2-AS2 survival associations across molecular data types. NAV2-AS2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAV2-AS2 RNA expression–survival associations across cancer types. High NAV2-AS2 expression shows unfavorable associations in BLCA, UVM, MESO, KIRP and SKCM, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NAV2-AS2 RNA expression.
This table summarizes NAV2-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NAV2-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAV2-AS2 shows lower tumor expression in KIRC, KIRP, LUAD, LUSC, KICH and UCEC. The KIRC box plot shows higher NAV2-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p < 0.001).
This table shows molecular features associated with NAV2-AS2 in patient tissues and cancer cell lines. In patient samples, NAV2-AS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
